ProSperA: Phase I Study to Evaluate Safety, Tolerability and Preliminary Efficacy of a Bispecific PSMAxCD3 Antibody in Men with Biochemical Recurrence of Prostate Cancer.
JOURNAL OF CLINICAL ONCOLOGY（2023）
Key words
Bispecific Antibodies
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined